Nucpaedia
Nucpaedia
Mechanism 10 of 16

Redox trapping in hypoxia

A nitroimidazole is reduced inside the cell to a radical anion. Oxygen, if present, re-oxidises it and the tracer leaves. Where there is no oxygen, reduction continues and the product binds covalently to whatever is nearby.

The switch is the point: retention is not proportional to anything, it is gated by pO₂. That gives a genuinely functional readout of the property that makes tumours radioresistant, and it is the basis of dose-painting research.

One constraint follows from the mechanism and is easy to forget: the reduction is enzymatic, so trapping requires viable cells. Necrotic tissue is profoundly hypoxic and completely unlabelled. Hypoxia imaging shows you cells that are alive and starving, not cells that are dead.

NORMOXIAHYPOXIAnitroreductasenitroreductaseO₂electron handed back —the tracer diffuses straight outreduction continues →covalent binding to macromoleculesboth require viable, enzymatically active cells — necrosis is not labelledNININININININININI
nitroimidazolecovalently boundre-oxidised, leaving
The same reaction, two endings. Nitroreductase reduces the tracer in both cells. On the left, oxygen hands the electron back and the molecule walks out again. On the right, with no oxygen to reverse it, reduction goes further and the product binds covalently to intracellular macromolecules. Both cells must be alive for any of this to happen — necrosis is unlabelled.

The agents

F-18 FMISOfluoromisonidazole · research

PET

F-18 · t½ 110 min · image at 2–4 h

NORMOXIAHYPOXIAnitroreductasenitroreductaseO₂re-oxidised → diffuses outreduced further → binds covalentlyNININININININININI
Handle
Nitroreductase, gated by pO₂
Trapping
Reduced to a radical anion; re-oxidised and released if oxygen is present, further reduced and covalently bound if it is not. A tumour-to-blood ratio above about 1.2–1.4 defines hypoxia.
Use
Radiotherapy dose-painting research, glioma, head and neck cancer.
Pitfall
Slow kinetics and high background give poor lesion contrast — the reason it has never entered routine practice despite thirty years of interest. Not FDA-approved.

F-18 FAZAfluoroazomycin arabinoside

PET

F-18 · t½ 110 min

BloodHypoxic cellnitroreductasecovalently boundmore hydrophilic → background clears fasterunbound tracer is cleared, not left in blood— the contrast FMISO never hadFAZAFAZAFAZAFAZAFAZAFAZA
Handle
Same nitroreductase mechanism
Trapping
More hydrophilic than FMISO, so background clears faster and contrast improves.
Use
Hypoxia imaging in trials, particularly head and neck.
Pitfall
Still investigational; absolute uptake remains low, so quantification is noise-limited.

Cu-64 ATSM—

PET

Cu-64 · t½ 12.7 h

BloodHypoxic cellCu(II) complex crosses freelyin a reducing cell Cu(II) → Cu(I)and the complex falls apartCucopper stranded insideATSMligand diffuses awayCuATSMCuCuATSMCuCuATSMCu
Handle
Intracellular reducing environment
Trapping
Different chemistry: the Cu(II) complex is reduced to Cu(I) in low-oxygen cells and dissociates, stranding the copper inside.
Use
Faster imaging than FMISO, with better contrast.
Pitfall
Retention depends on cellular redox state as much as on pO₂ itself, which complicates the claim that the image is a hypoxia map. Tumour-type dependent.